摘要
背景与目的:以多西他赛为核心的化疗方案已经成为激素抵抗性前列腺癌治疗的一线方案。本文初步比较多西他赛联合泼尼松或米托蒽醌联合泼尼松在雄激素抵抗性前列腺癌中的疗效差异,进一步探讨这两种方案的毒副反应。方法:入选雄激素抵抗性前列腺癌患者共83例,其中44例给予多西他赛75mg/m2d1静脉滴注联合泼尼松,5mg,每天2次,d1～21口服方案治疗(简称多西他赛组),39例给予米托蒽醌12mg/m2d1静脉滴注联合泼尼松,5mg,每天2次,d1～21口服方案治疗(简称米托蒽醌组)。两方案均以21天为1周期,平均治疗5周期。结果:多西他赛组中13.6%(6/44)完全缓解(治疗后PSA下降至4.0ng/ml以下),29.5%(13/44)部分缓解,29.5%(13/44)稳定,27.3%(12/44)进展。缓解和稳定患者的PSA进展中位时间是37.8周(12～101周)。进展的12例患者接受了后续的米托蒽醌组挽救治疗,结果部分缓解16.7%(2/12),稳定25.0%(3/12),2例患者死于疾病进展。米托蒽醌组中7.7%(3/39)完全缓解,25.6%(10/39)部分缓解,25.6%(10/39)稳定,41.0%(16/39)进展。缓解和稳定患者的PSA进展中位时间是25.3周(8～61周)。进展的14例患者接受了后续的多西他赛组方案的挽救治疗,结果完全缓解7.1%(1/14),部分缓解35.7%(5/14),稳定21.4%(3/14),4例患者死于疾病进展。毒性评估:接受多西他赛组治疗者44例,Ⅲ～Ⅳ度骨髓抑制9例(2例因不能耐受化疗退出),Ⅱ度骨髓抑制14例;接受米托蒽醌组治疗者39例,Ⅲ～Ⅳ度骨髓抑制4例,Ⅱ度骨髓抑制12例。结论:多西他赛组或米托蒽醌组均是治疗雄激素抵抗性前列腺癌的有效化疗方案。两种方案对中国的前列腺癌患者的治疗效果比较接近,但米托蒽醌联合泼尼松的治疗方案的副作用略轻。两种方案交替使用仍可产生部分的反应率,两种方案可以互为挽救方案,且多西他赛联合泼尼松作为挽救方案疗效好于米托蒽醌联合泼尼松。
Background and purpose： Chemotherapy with docetaxel has become the first line treatment for hormone refractory prostate cancer. To preliminarily investigate the efficacy of docetaxel plus prednisone and mitoxantrone plus prednisone for treating metastatic hormone-refractory prostate cancer and to further evaluate its adverse events in Chinese patients. Methods： 83 patients with metastatic hormone-refractory prostate cancer were candidates for the trial and given a combination of docetaxel 75 mg/m^2 intravenously on d 1 or mitoxantrone 12 mg/m^2 on day 1 plus prednisone 5 mg twice daily on d 1 -21, 21 days a cycle. Serum PSA level, relief of bone pain, myelosuppression, and vomiting were recorded and calculated. Results： Docetaxel plus prednisone were administered to 44 patients, 13.6% （6/44） of them got a complete response; 29.5% （13/44） achieved a partial response; 29.5% （13/44） had stable disease; and 27.3% （12/44） progressed. The average time to PSA progression was 37.8 weeks （ 12 - 101 weeks） in the responsive and stable disease patients. The 12 patients with progressive disease were given MP as a salvage therapy, and 16.7% （2/12） achieved a partial response, 25.0% （3/12） had stable disease. Only 2 patients died of disease aggravation. Mitoxantrone plus prednisone were given to 39 patients, and 7.7% （3/39） of them got a complete response; 25.6% （10/39） achieved a partial response; 25.6% （10/39） had a stable disease; and 41.0% （16/39） of patients progressed. The mean time to PSA progression was 25.3 weeks （ 8 - 61 weeks） in the responsive and stable disease patients. The 14 patients with progressive disease were administered DP as a salvage therapy, and 7.1% （1/14） achieved a complete response, 35.7% （5/14） got a partial response, 21.4% （3/14） had stable disease and from the new baseline. Four patients died at the last follow-up. Conclusions： In Chinese patients, docetaxel plus prednisone is better than mitoxantrone plus prednisone in PSA response rate and PSA control, but there occurs a bit more toxicity. When the tumor is resistant to one regimen, the other might be still effective in controlling the disease from progression.
出处
《中国癌症杂志》
CAS
CSCD
2007年第3期236-239,共4页
China Oncology
